What is NDC 62756-452?

62756-452 is the product NDC for BYNFEZIA Pen (octreotide acetate), Octreotide acetate 2.5 mg/mL injection, listed with the FDA by Sun Pharmaceutical Industries, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

BYNFEZIA Pen (Octreotide acetate).

Sun Pharmaceutical Industries, Inc., NDC labeler code 62756. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for BYNFEZIA Pen?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

BYNFEZIA Pen NDC 62756-452 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)62756-452Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62756-0452Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62756-452-36	62756045236	1 CARTRIDGE in 1 CARTON (62756-452-36) / 2.8 mL in 1 CARTRIDGEMarketed from Feb 24, 2025
62756-452-37	62756045237	2 CARTRIDGE in 1 CARTON (62756-452-37) / 2.8 mL in 1 CARTRIDGEMarketed from Feb 24, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): BYNFEZIA Pen
Generic name (nonproprietary): octreotide acetate
Active ingredients: Octreotide acetate — 2.5 mg/mL
Dosage form: Injection
Route: Subcutaneous
Labeler: Sun Pharmaceutical Industries, Inc.NDC labeler code 62756
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 213224
Marketing start: Feb 24, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Somatostatin Receptor Agonists (Mechanism)
Identifiers: Product ID 62756-452_ee3c8bae-88f0-4b76-80af-98a3e3312585SPL ID ee3c8bae-88f0-4b76-80af-98a3e3312585SPL set ID 20ed4e79-ad4c-426f-859d-83790c00439bRxCUI 2360543, 2360548UNII 75R0U2568I
Pharmacologic class: Somatostatin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N462756045236 followed by a unit qualifier and the quantity

Package 62756-0452-36. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 21, 2025.

Indications (excerpt from the label)

BYNFEZIA PEN is a s o matostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor 1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. (1 .1) Carcinoid Tumors : For the symptomatic treatment of patients with m eta static c a rcinoid t u mo rs where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. (1 .2) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors . (…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 62756-452

What is NDC 62756-452?: 62756-452 is the product NDC for BYNFEZIA Pen (octreotide acetate), Octreotide acetate 2.5 mg/mL injection, listed with the FDA by Sun Pharmaceutical Industries, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: BYNFEZIA Pen (Octreotide acetate).
What is the active ingredient?: Octreotide acetate.
Who is the labeler?: Sun Pharmaceutical Industries, Inc., NDC labeler code 62756. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for BYNFEZIA Pen?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

BYNFEZIA Pen (Octreotide acetate) NDC 62756-452